Memory B Cell Antibodies to HIV-1 gp140 Cloned from Individuals Infected with Clade A and B Viruses
Author Information
Author(s): Mouquet Hugo, Klein Florian, Scheid Johannes F., Warncke Malte, Pietzsch John, Oliveira Thiago Y. K., Velinzon Klara, Seaman Michael S., Nussenzweig Michel C.
Primary Institution: Laboratory of Molecular Immunology, The Rockefeller University
Hypothesis
Understanding the antibody response to HIV-1 in humans that show broad neutralizing serologic activity is crucial for vaccine development.
Conclusion
The study identified 189 new anti-gp140 antibodies from HIV-infected individuals, showing diverse responses and some with significant neutralizing activity.
Supporting Evidence
- 75% of the antibodies were polyreactive, indicating a diverse immune response.
- Two antibodies ranked in the top 5% of neutralizers identified in the study.
- The antibody response was characterized by high levels of somatic hypermutation.
- Most anti-gp120 antibodies exhibited measurable levels of neutralization activity.
Takeaway
Scientists studied blood from people infected with HIV to find new antibodies that can fight the virus, helping to create better vaccines.
Methodology
The study used single-cell antibody cloning methods to obtain antibodies from memory B cells of HIV-infected patients.
Potential Biases
Potential bias in selecting B cell clones due to the use of a clade B gp140 protein as bait.
Limitations
The study did not isolate broadly neutralizing antibodies from all patients, and the efficiency of the antibody capture method may limit findings.
Participant Demographics
Participants included two African donors infected with clade A HIV viruses and one Caucasian donor with a clade B virus.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website